Your browser doesn't support javascript.
loading
Next-generation sequencing in hematologic malignancies: what will be the dividends?
Merker, Jason D; Valouev, Anton; Gotlib, Jason.
Afiliación
  • Merker JD; Department of Pathology, Stanford University School of Medicine, Stanford, CA 94304, USA.
Ther Adv Hematol ; 3(6): 333-9, 2012 Dec.
Article en En | MEDLINE | ID: mdl-23606936
The application of high-throughput, massively parallel sequencing technologies to hematologic malignancies over the past several years has provided novel insights into disease initiation, progression, and response to therapy. Here, we describe how these new DNA sequencing technologies have been applied to hematolymphoid malignancies. With further improvements in the sequencing and analysis methods as well as integration of the resulting data with clinical information, we expect these technologies will facilitate more precise and tailored treatment for patients with hematologic neoplasms.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Ther Adv Hematol Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Ther Adv Hematol Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos